Actively Recruiting
Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease
Led by Gitte Fredberg Persson MD PhD · Updated on 2024-04-16
1200
Participants Needed
11
Research Sites
611 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy. Patients with any category of OMD from any non-hematological cancer are eligible for inclusion. Local ablative therapy (LAT) includes surgical metastasectomy, radiotherapy, thermal ablation, and electroporations. The primary objective is to assess the time to failure of LAT strategy in patients with OMD from any primary cancer treated with all LAT modalities.
CONDITIONS
Official Title
Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histology or cytology proven non-haematological cancer
- Stage IV disease
- ECOG performance status 64; 2
- Life expectancy > 6 months
- A baseline scan (PET-CT, CT, or MRI) within 42 days of inclusion
- Controlled primary tumor or planned local ablative therapy if progressing
- Oligometastatic disease with up to 5 metastases, including oligoprogression
- All oligometastatic lesions planned for definitive local ablative therapy
- Local ablative therapy deemed clinically relevant by treating or multidisciplinary team
- Ability to understand and willing to sign informed consent
You will not qualify if you...
- Pregnancy
- Diffuse cancer that cannot be locally ablated (e.g., leptomeningeal carcinomatosis, malignant pleural effusions, lymphangitic carcinomatosis, peritoneal carcinomatosis)
- Local ablative therapy deemed unsafe by multidisciplinary team
- For patients receiving stereotactic radiotherapy, metastatic lesions larger than 5 cm or exceeding radiation dose constraints if previously treated
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Copenhagen University Hospital Rigshospitalet
Copenhagen, Capital Region of Denmark, Denmark, 2100
Not Yet Recruiting
2
Copenhagen University Hospital Herlev and Gentofte
Herlev, Capital Region of Denmark, Denmark, 2730
Actively Recruiting
3
Hillerød Hospital
Hillerød, Capital Region of Denmark, Denmark, 3400
Not Yet Recruiting
4
Aarhus University Hospital
Aarhus, Central Jutland, Denmark, 8200
Not Yet Recruiting
5
Gødstrup Hospital
Herning, Central Jutland, Denmark, 7400
Not Yet Recruiting
6
Danish Center for Particle Therapy
Aarhus, Central Region Denmark, Denmark, 8200
Not Yet Recruiting
7
Aalborg University Hospital
Aalborg, Northern Region of Denmark, Denmark, 9000
Not Yet Recruiting
8
Zealand University Hospital, Roskilde and Næstved
Roskilde, Region Sjælland, Denmark, 4000
Not Yet Recruiting
9
Odense University Hospital
Odense, Southern Denmark Region, Denmark, 5000
Not Yet Recruiting
10
Sønderborg Hospital
Sønderborg, Southern Denmark Region, Denmark, 6400
Not Yet Recruiting
11
Vejle Hospital
Vejle, Southern Denmark Region, Denmark, 7100
Not Yet Recruiting
Research Team
M
Michael RT Laursen, MD
CONTACT
G
Gitte F Persson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here